| Literature DB >> 35962372 |
Gayatri Marathe1,2, Erica E M Moodie1, Marie-Josée Brouillette2,3, Joseph Cox1,3, Curtis Cooper4, Charlotte Lanièce Delaunay1,3, Brian Conway5, Mark Hull6, Valérie Martel-Laferrière7, Marie-Louise Vachon8, Sharon Walmsley9, Alexander Wong10, Marina B Klein11,12,13.
Abstract
BACKGROUND: Depression is common in the human immunodeficiency virus (HIV)-hepatitis C virus (HCV) co-infected population. Demographic, behavioural, and clinical data collected in research settings may be of help in identifying those at risk for clinical depression. We aimed to predict the presence of depressive symptoms indicative of a risk of depression and identify important classification predictors using supervised machine learning.Entities:
Keywords: Depressive symptoms; HIV-HCV co-infection; Random forests; Supervised machine learning
Mesh:
Year: 2022 PMID: 35962372 PMCID: PMC9375382 DOI: 10.1186/s12874-022-01700-y
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.612
Candidate predictors used in the random forest algorithms
| Category | All Candidate Predictors |
|---|---|
| Questions related to mental health | Psychiatric institution or psychiatric hospital stay; Psychiatric diagnoses in chart reviews; Use of psychotropic medications (e.g., antidepressants, sedative hypnotics, atypical and typical anti-psychotics) |
| HR-QoL | EQ-5D-3L—standardized instrument - Descriptive system (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) - Current health state with a visual analog scale – scores range between 0–100 |
| Sociodemographic characteristics | Age; Gender; Race/ethnicity; Immigration status; Living situation; Shared accommodation details; Education; Employment; Monthly income; Source of income |
| Behavioral characteristics | Injection drug use (ever/P6M); Non-injection drug use (ever/P6M); Needle/equipment sharing behaviors (ever/P6M); Snort (ever/P6M); Sharing behaviors for snorting apparatus (ever/P6M); Marijuana use; Therapy for drug addiction; Alcohol use (ever/P6M); Alcohol abuse; Smoking (ever/P6M); Sexual orientation; number of sexual partners; Sex work; Incarceration (ever/P6M); Tattoos; Body piercing |
| Clinical characteristics | BMI category; HIV viral load; CD4 count; HCV RNA; HIV disease stage; AIDS defining illness; health services used in the past 6 months (walk-in clinic, emergency room, inpatient, general practitioner, HIV clinic and specialist); Previous interferon-based HCV treatment; current antiretroviral therapy; Hepatitis B diagnosis; sexually transmitted disease diagnosis; end-stage liver disease (cirrhosis, ascites, varices, portal hypertension, encephalopathy, hepatocellular carcinoma); APRI, a measure of liver fibrosis; cardiovascular disease; autoimmune disease; hypertension; thyroid disease; psoriasis; lipodystrophy; hypercholesterolemia |
Abbreviations: HR-QoL Health related quality of life, EQ-5D-3L EuroQoL-5Dimension-3Level, P6M in the past 6 months, BMI Body Mass Index, HIV Human Immunodeficiency Virus, CD4 Cluster of differentiation 4 receptor, HCV Hepatitis C virus, RNA Ribonucleic acid, AIDS Acquired Immunodeficiency Syndrome, APRI Aspartate Aminotransferase (AST) to platelet ratio
Baseline characteristics of participants in the study sample (n = 717)
| Characteristics | Participants ( |
|---|---|
| Age | 49 (43, 54) |
| Gender – Male | 522 (73) |
| Race/Ethnicity | |
| Asian | 11 (2) |
| Black | 28 (4) |
| White | 541 (76) |
| Metis | 32 (5) |
| First nation | 102 (14) |
| Hispanic/Latino | 7 (1) |
| Born outside Canada | 64 (9) |
| Education—High school educated | 376 (52) |
| Employment—Unemployed | 525 (73) |
| Monthly income—< $1500 | 543 (76) |
| Revenue Source—Welfare | 332 (46) |
| Current injection drug use | 244 (34) |
| Current alcohol use | 444 (62) |
| Current smoking | 534 (75) |
| BMI category | |
| Underweight (< 18.5 kg/m2) | 40 (6) |
| Normal weight (18.5–25 kg/m2) | 312 (44) |
| Overweight (25–29.9 kg/m2) | 189 (26) |
| Obese (30.0 kg/m2) | 87 (12) |
| End-stage Liver disease | 27 (4) |
| HIV clinical stage—A1 (Asymptomatic and CD4 > 500 cells/μl) | 248 (35) |
| Past AIDS related illness | 28 (4) |
| CES-D-10 score | 10 (5, 15) |
| CES-D-10 category—≥ 10 | 382 (53) |
| Depression diagnosis | 68 (10) |
| Prescribed antidepressant medications | 320 (45) |
| HR-QoL using EQ-5D-3L instrument | |
| Anxiety/depression | |
| Not anxious or depressed | 352 (49) |
| Moderately anxious or depressed | 302 (42) |
| Extremely anxious or depressed | 60 (8) |
| Current health state (visual analog scale) | 70 (56, 80) |
Abbreviations: IQR Interquartile range, CES-D-10 Center for Epidemiologic Studies Depression Scale-10, AIDS Acquired Immunodeficiency Syndrome, HIV Human Immunodeficiency Virus, BMI Body Mass Index, HR-QoL Health related quality of life, EQ-5D-3L EuroQoL-5Dimension-3Level
Fig. 1Receiver Operating Characteristic (ROC) curve for the A Full algorithm (x = 137) and B Reduced algorithm (x = 46)
Performance evaluation in the primary analysis
| Evaluation measure (95% CI) | Full algorithm (x = 137) | Reduced algorithm (x = 46) |
|---|---|---|
| AUC | 0.82 (0.78–0.86) | 0.76 (0.71–0.81) |
| Sensitivity | 0.77 (0.70–83) | 0.70 (0.63–0.76) |
| Specificity | 0.73 (0.66–0.79) | 0.70 (0.63–0.76) |
| PPV | 0.74 (0.68–0.80) | 0.70 (0.63–0.76) |
| NPV | 0.76 (0.69–0.82) | 0.69 (0.62–0.76) |
| LR + | 2.8 (2.2–3.6) | 2.3 (1.8–2.9) |
| LR - | 0.3 (0.2 – 0.4) | 0.4 (0.3–0.6) |
Abbreviations: CI Confidence interval, AUC Area under the Receiver Operating Characteristic curve, PPV Positive Predictive Value, NPV Negative Predictive Value, LR + Positive likelihood ratio, LR—Negative likelihood ratio
Fig. 2Predictor importance plots: A Full algorithm and B Reduced algorithm. Abbreviations: BMI: Body Mass Index; P6M: In the past 6 months; CD4: Cluster of differentiation 4 receptor; EQ-5D-3L: EuroQoL-5Dimension-3Level; RNA: Ribonucleic acid; Hep B: Hepatitis B virus
Comparison of performance evaluation measures for primary and additional analyses
| Sr. No | Analysis | OOB error | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|
| 1 | Full algorithm (x = 137) | 0.16 | 0.82 (0.78–0.86) | 0.77 (0.70–0.83) | 0.73 (0.66–0.79) |
| 2 | Reduced algorithm (x = 46) | 0.20 | 0.76 (0.71–0.81) | 0.70 (0.63–0.76) | 0.70 (0.63–0.76) |
| 1 | Full algorithm (x = 137) | 0.17 | 0.74 (0.66–0.82) | 0.70 (0.58–0.80) | 0.64 (0.52–0.76) |
| 2 | Reduced algorithm (x = 46) | 0.23 | 0.60 (0.50–0.69) | 0.73 (0.61–0.82) | 0.37 (0.26–0.50) |
| 1 | Full algorithm (x = 137) | 0.17 | 0.85 (0.81–0.89) | 0.91 (0.87–0.95) | 0.67 (0.59–0.74) |
| 2 | Reduced algorithm (x = 46) | 0.19 | 0.79 (0.74–0.83) | 0.83 (0.77–0.87) | 0.60 (0.52–0.67) |
| 1 | Full algorithm (x = 137) | 0.15 | 0.80 (0.76–0.85) | 0.62 (0.54–0.70) | 0.81 (0.76–0.86) |
| 2 | Reduced algorithm (x = 46) | 0.20 | 0.79 (0.74–0.83) | 0.45 (0.37–054) | 0.87 (0.82–0.91) |
| 1 | Full algorithm (x = 137) | 0.14 | 0.87 (0.83–0.91) | 0.55 (0.45–0.65) | 0.95 (0.91–0.97) |
| 2 | Reduced algorithm (x = 46) | 0.17 | 0.73 (0.67–0.79) | 0.27 (0.19–0.36) | 0.94 (0.91–0.97) |
| 0.16 | 0.84 (0.80–0.87) | 0.77 (0.70–0.83) | 0.73 (0.67–80) | ||
Abbreviations: OOB Out-of-Bag Samples, AUC Area under the Receiver Operating Characteristic curve, CI Confidence interval, CES-D-10 Center for Epidemiologic Studies Depression Scale-10